Literature DB >> 8572194

Quantitation of hepatic glucose fluxes and pathways of hepatic glycogen synthesis in conscious mice.

D Massillon1, W Chen, M Hawkins, R Liu, N Barzilai, L Rossetti.   

Abstract

Mice were studied with the euglycemic hyperinsulinemic and the hyperglycemic clamp techniques after a 6-h fast: 1) euglycemic (6.7 +/- 0.2 mM) hyperinsulinemia (approximately 800 microU/ml); 2) hyperglycemic (15.3 +/- 0.4 mM) hyperinsulinemia (approximately 800 microU/ml). All mice received an infusion of [3-3H]glucose and [U-14C]lactate. Basal hepatic glucose production (HGP) averaged approximately 170 mumol.kg-1.min-1 in both groups. During euglycemic and hyperglycemic hyperinsulinemia, HGP decreased by 53% (to 76.7 +/- 11.1 mumol.kg-1.min-1; P < 0.01) and 74% (to 43.3 +/- 7.2 mumol.kg-1.min-1; P < 0.01), respectively. Hyperglycemia increased glucose cycling (by 2.1-fold; P < 0.01) and the contribution of gluconeogenesis to HGP (88 vs. 43%; P < 0.01) while decreasing that of glycogenolysis (12 vs. 57%; P < 0.01). The percentage of neosynthetized hepatic glycogen formed via the direct pathway was markedly increased during hyperglycemia (53 +/- 2% vs. 23 +/- 3%; P < 0.01): These data indicate that the assessment of hepatic glucose fluxes can be accomplished in conscious unrestrained mice and that, in the presence of hyperinsulinemia, hyperglycemia causes 1) a further inhibition of HGP mainly via inhibition of glycogenolysis and increase in hepatic glucose cycling; and 2) about a fivefold stimulation in the direct pathway of hepatic glycogen formation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8572194     DOI: 10.1152/ajpendo.1995.269.6.E1037

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  9 in total

1.  Restoration of liver insulin signaling in Insr knockout mice fails to normalize hepatic insulin action.

Authors:  Haruka Okamoto; Silvana Obici; Domenico Accili; Luciano Rossetti
Journal:  J Clin Invest       Date:  2005-05       Impact factor: 14.808

2.  Peripheral but not hepatic insulin resistance in mice with one disrupted allele of the glucose transporter type 4 (GLUT4) gene.

Authors:  L Rossetti; A E Stenbit; W Chen; M Hu; N Barzilai; E B Katz; M J Charron
Journal:  J Clin Invest       Date:  1997-10-01       Impact factor: 14.808

3.  Enhanced glucose cycling and suppressed de novo synthesis of glucose-6-phosphate result in a net unchanged hepatic glucose output in ob/ob mice.

Authors:  R H J Bandsma; A Grefhorst; T H van Dijk; F H van der Sluijs; A Hammer; D-J Reijngoud; F Kuipers
Journal:  Diabetologia       Date:  2004-12-01       Impact factor: 10.122

4.  Cannabinoid receptor 1 (CB1) antagonism enhances glucose utilisation and activates brown adipose tissue in diet-induced obese mice.

Authors:  M Bajzer; M Olivieri; M K Haas; P T Pfluger; I J Magrisso; M T Foster; M H Tschöp; K A Krawczewski-Carhuatanta; D Cota; S Obici
Journal:  Diabetologia       Date:  2011-10-11       Impact factor: 10.122

5.  Endogenous glucose production is inhibited by the adipose-derived protein Acrp30.

Authors:  T P Combs; A H Berg; S Obici; P E Scherer; L Rossetti
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

6.  Forkhead Box O6 (FoxO6) Depletion Attenuates Hepatic Gluconeogenesis and Protects against Fat-induced Glucose Disorder in Mice.

Authors:  Virtu Calabuig-Navarro; Jun Yamauchi; Sojin Lee; Ting Zhang; Yun-Zi Liu; Kelsey Sadlek; Gina M Coudriet; Jon D Piganelli; Chun-Lei Jiang; Rita Miller; Mark Lowe; Hideyoshi Harashima; H Henry Dong
Journal:  J Biol Chem       Date:  2015-05-05       Impact factor: 5.157

7.  Severe impairment in liver insulin signaling fails to alter hepatic insulin action in conscious mice.

Authors:  Christoph Buettner; Rima Patel; Evan D Muse; Sanjay Bhanot; Brett P Monia; Rob McKay; Silvana Obici; Luciano Rossetti
Journal:  J Clin Invest       Date:  2005-05       Impact factor: 14.808

8.  The AMP-activated protein kinase alpha2 catalytic subunit controls whole-body insulin sensitivity.

Authors:  Benoit Viollet; Fabrizio Andreelli; Sebastian B Jørgensen; Christophe Perrin; Alain Geloen; Daisy Flamez; James Mu; Claudia Lenzner; Olivier Baud; Myriam Bennoun; Emmanuel Gomas; Gaël Nicolas; Jørgen F P Wojtaszewski; Axel Kahn; David Carling; Frans C Schuit; Morris J Birnbaum; Erik A Richter; Rémy Burcelin; Sophie Vaulont
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

9.  Glucokinase activator PSN-GK1 displays enhanced antihyperglycaemic and insulinotropic actions.

Authors:  M C T Fyfe; J R White; A Taylor; R Chatfield; E Wargent; R L Printz; T Sulpice; J G McCormack; M J Procter; C Reynet; P S Widdowson; P Wong-Kai-In
Journal:  Diabetologia       Date:  2007-04-06       Impact factor: 10.122

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.